Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Buy rating reiterated by HC Wainwright with a $12.00 price target

ME Staff
-
0

Analyst Ratings For Applied Genetic Technologies Corp (NASDAQ:AGTC)

Today, HC Wainwright reiterated its Buy rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) with a price target of $12.00.

There are 3 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy with a consensus target price of $9.60 per share, a potential 138.81% upside.

Some recent analyst ratings include

  • 7/25/2019-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Buy rating reiterated by HC Wainwright with a $12.00 price target
  • 5/8/2019-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Outperform rating reiterated by Wedbush with a $11.00 price target
  • 12/13/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) gets downgraded to Market Perform by BMO Capital Markets with a price target of $5.00
  • 9/11/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) gets downgraded to Neutral by Chardan Capital with a price target of $5.00
  • 1/17/2018-Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Hold rating reiterated by Cantor Fitzgerald with a $9.00 price target
  • On 12/14/2018 Susan B Washer, Insider, bought 2,380 with an average share price of $3.34 per share and the total transaction amounting to $7,949.20.
  • On 12/14/2018 William A. Sullivan, CFO, bought 3,000 with an average share price of $3.33 per share and the total transaction amounting to $9,990.00.
  • On 12/14/2018 William Aliski, Director, bought 6,000 with an average share price of $3.25 per share and the total transaction amounting to $19,500.00.
  • On 11/16/2016 Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
  • On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
  • On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
  • On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.

About Applied Genetic Technologies Corp (NASDAQ:AGTC)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. Read More…

Recent Trading Activity for Applied Genetic Technologies Corp (NASDAQ:AGTC)
Shares of Applied Genetic Technologies Corp closed the previous trading session at 4.07 up +0.010 0.25% with 4.08 shares trading hands.